4.7 Article

Structural basis for plasmep sin V inhibition that blocks export of malaria proteins to human erythrocytes

Journal

NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 22, Issue 8, Pages 590-596

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb.3061

Keywords

-

Funding

  1. Victorian State Government Operational Infrastructure Support
  2. Australian Government National Health and Medical Research Council (NHMRC) Independent Research Institute Infrastructure Support Scheme
  3. Australian Cancer Research Foundation
  4. NHMRC [1057960, 637406, 1010326]
  5. University of Melbourne
  6. National Health and Medical Research Council of Australia [1057960] Funding Source: NHMRC

Ask authors/readers for more resources

Plasmepsin V, an essential aspartyl protease of malaria parasites, has a key role in the export of effector proteins to parasite-infected erythrocytes. Consequently, it is an important drug target for the two most virulent malaria parasites of humans, Plasmodium falciparum and Plasmodium vivax. We developed a potent inhibitor of plasmepsin V, called WEHI-842, which directly mimics the Plasmodium export element (PEXEL). WEHI-842 inhibits recombinant plasmepsin V with a half-maximal inhibitory concentration of 0.2 nM, efficiently blocks protein export and inhibits parasite growth. We obtained the structure of P. vivax plasmepsin V in complex with WEHI-842 to 2.4-angstrom resolution, which provides an explanation for the strict requirements for substrate and inhibitor binding. The structure characterizes both a plant-like fold and a malaria-specific helix-turn-helix motif that are likely to be important in cleavage of effector substrates for export.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available